GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
8th August 2025 Uncategorised 0Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.S. The deal will see BioNTech pay out cash and extend royalties from sales of its COVID vaccine to CureVac and its mRNA partner GSK. The resolution does not eliminate separate mRNA litigation brought by GSK against Pfizer and BioNTech.
More: GSK collects 0M as BioNTech, Pfizer settle mRNA patent spat with CureVac
Source: fierce